-
Information-Publications
-
FOXA3 regulates cholesterol metabolism to compensate for low uptake during the progression of lung adenocarcinomaDetails
-
Targeting fibrinogen-like protein 1 enhances immunotherapy in hepatocellular carcinomaDetails
-
Fully human single-domain antibody targeting a highly conserved cryptic epitope on the Nipah virus G proteinDetails
-
Developing PspCas13b-based enhanced RESCUE system, eRESCUE, with efficient RNA base editingDetails
-
Transcription-wide impact by RESCUE-induced off-target single nucleotide variants in mammalian cellDetails
-
nCas9 Engineering for Improved Target Interaction Presents an Effective Strategy to Enhance Base EditingDetails
-
"Heyuan Liji" is a joint venture between Heyuan Biotechnology (stock code: 688238) and Liji Biotechnology, specializing in the "Liji Biotechnology" and "Life-ilab" reagent brands